A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

UBT251: Relative change in body weight

Measured as %.

Time frame: From baseline (week 0) to week 40

UBT251: Change in body weight

Measured as kilogram (kg).

Time frame: From baseline (week 0) to week 40

UBT251 vs placebo: Change in HbA1c

Measured as %-point.

Time frame: From baseline (week 0) to 12 weeks on a given maintenance dose (week 16, 28 and 40)

Change in HbA1c

Measured as %-point.

Time frame: From baseline (week 0) to week 40

Change in homeostasis model assessment of insulin resistance (HOMA2-IR)

Measured as ratio to baseline.

Time frame: From baseline (week 0) to week 40

Change in homeostasis model assessment of beta-cell function (HOMA2-B)

Measured as ratio to baseline.

Time frame: From baseline (week 0) to week 40

Change in fasting plasma glucose (FPG)

Measured as millimoles per litre (mmol/L).

Time frame: From baseline (week 0) to 12 weeks on a given maintenance dose (week 16, 28 and 40)

CGM: Change in time in range (TIR) 3.9-10.0 mmol/L (70-180 milligrams per deciliter (mg/dL))

Measured as %-points.

Time frame: From baseline (week -2 to week 0) to week 14- 16, week 26-28 and week 38-40, respectively

UBT251 vs placebo: Relative change in body weight

Measured as %.

Time frame: From baseline (week 0) to week 40

UBT251 vs placebo: Change in body weight

Measured as kg.

Time frame: From baseline (week 0) to week 40

Change in body mass index (BMI)

Measured as Kilograms per square meter (kg/m\^2).

Time frame: From baseline (week 0) to week 40

Change in waist circumference

Measured as centimeter (cm).

Time frame: From baseline (week 0) to week 40

Change in waist-to-height ratio (WHtR)

Time frame: From baseline (week 0) to week 40

Change in systolic blood pressure (SBP)

Measured as millimetres of mercury (mmHg).

Time frame: From baseline (week 0) to week 40

Change in diastolic blood pressure (DBP)

Measured as mmHg.

Time frame: From baseline (week 0) to week 40

Change in pulse rate

Measured in beats/min.

Time frame: From baseline (week 0) to week 40

Change in high sensitivity C-Reactive Protein (hsCRP)

Measured as ratio to baseline.

Time frame: From baseline (week 0) to week 40

Change in total cholesterol

Measured as ratio to baseline.

Time frame: From baseline (week 0) to week 40

Change in high-density lipoprotein (HDL) cholesterol

Measured as ratio to baseline.

Time frame: From baseline (week 0) to week 40

Change in low-density lipoprotein (LDL) cholesterol

Measured as ratio to baseline.

Time frame: From baseline (week 0) to week 40

Change in triglycerides

Measured as ratio to baseline.

Time frame: From baseline (week 0) to week 40

Change in urine albumin creatinine ratio (UACR)

Measured as ratio to baseline.

Time frame: From baseline (week 0) to 12 weeks on a given maintenance dose (week 16, 28 and 40)

Change in eGFR (creatinine-cystatin C-based CKD-EPI 2021)

Measured in milliliters per minute per 1.73 square meters (mL/min/1.73 m\^2).

Time frame: From baseline (week 0) to week 40

Number of treatment-emergent adverse events (TEAEs)

Measured as number of events.

Time frame: From baseline (week 0) to week 46